NAS10029,813+0.55%S&P7,744+0.28%GOLD$4,077+0.07%BTC$81,598+0.98%VIX16.87−3.71%latest tape · as of 20:04 UTC
The Screen · Real Estate · REIT - Healthcare Facilities
Diversified Healthcare Trust
DHC · Nasdaq · USD · Market cap $1.9B
Diversified Healthcare Trust is a real estate investment trust focused on owning high-quality healthcare properties located throughout the United States.
FAIL · Does not pass the screen
7.86 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 5 days ago
Screened 2026-10-23 · the tape above runs as of 20:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price7.86 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.00)
Last reviewed23 Oct 2026 (5 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 7.86 against the desk's fair-value range, base estimate 10.55, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-10-23
Ethical does not pass the values gate
Price7.86 USD
Fair value10.55
Ethical score70.0/100
Our investment reviews on this name
2026-10-21Read Markdown7.61+3.3% to today Accumulation gives way to Markdown after a 6% slide in 3 weeks
2026-10-02Read Accumulation8.12-3.2% to today Markdown gives way to Accumulation after an 8% slide in 5 weeks
2026-08-26Read Markdown8.82-10.9% to today ✓Markup gives way to Markdown with volume flow in agreement
2026-07-02Read Markup9.03-13.0% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Diversified Healthcare Trust holds its Markdown at $7.86. The statistical read favours the sellers, held for 315 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 315 days
Price at the screen
$7.86
Valuation
N/A trailing · -17.68 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.27
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
55.05%
Below 33%
Interest-bearing debt is 55.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
2.51%
Below 49%
Money owed to the company is 2.5% of assets, under the 49% limit.
Pass
Revenue purity
0.38%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Diversified Healthcare Trust's business is in a permissible area, but its interest-bearing debt is about 55% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DHC's ethical verdict changes
Today DHC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 37.2% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +34% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Healthcare REIT Loses Money On Shrinking Revenue
Picture a landlord whose tenants in clinics and labs keep cutting rents while costs keep rising. Diversified Healthcare Trust owns US medical properties yet posted a 5% revenue drop, a 21% negative profit margin and an 18% negative return on equity. With a forward P/E of minus 19.3 times the market is already treating the business as value destructive, and our screen finds no opportunity despite the ethical pass.
The numbers show a company stuck in contraction rather than recovery. Analyst targets sit around 10 dollars against the current 9.16 dollar price, offering only a thin margin of safety that does not offset the underlying losses. Unknown competitive protection and no clear growth path leave the investment case thin.
High debt loads typical of REITs amplify every downturn in occupancy and reimbursement rates. Currency and policy shifts in US healthcare add further volatility that the current earnings trajectory cannot absorb. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DHC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$7.69+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$7.69+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$7.69+1.1%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown · changed$7.61+1.5%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-10-14Accumulation$7.50-7.6%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-10-02Accumulation · changed$8.12-7.9%Entry 6
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 7.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-08-26Markdown · changed$8.82-3.7%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-07-26Markup$9.16+1.4%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-07-18Markup$9.03+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 53% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 165%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (4 analysts) rates it none, with a mean price target of $8.
2026-07-03Markup$9.03+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
